Sensei Biotherapeutics, Inc.
SNSE
$8.05
-$0.15-1.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.67M | 11.54M | 12.07M | 12.34M | 13.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.95M | 26.93M | 29.51M | 30.96M | 32.68M |
| Operating Income | -23.95M | -26.93M | -29.51M | -30.96M | -32.68M |
| Income Before Tax | -24.14M | -26.82M | -29.03M | -30.16M | -29.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.14 | -26.82 | -29.03 | -30.16 | -29.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.14M | -26.82M | -29.03M | -30.16M | -29.80M |
| EBIT | -23.95M | -26.93M | -29.51M | -30.96M | -32.68M |
| EBITDA | -23.52M | -26.19M | -28.48M | -29.64M | -31.36M |
| EPS Basic | -19.16 | -21.31 | -23.08 | -24.01 | -23.78 |
| Normalized Basic EPS | -11.45 | -12.79 | -13.92 | -14.42 | -15.09 |
| EPS Diluted | -19.16 | -21.31 | -23.08 | -24.01 | -23.78 |
| Normalized Diluted EPS | -11.45 | -12.79 | -13.92 | -14.42 | -15.09 |
| Average Basic Shares Outstanding | 5.04M | 5.04M | 5.03M | 5.02M | 5.01M |
| Average Diluted Shares Outstanding | 5.04M | 5.04M | 5.03M | 5.02M | 5.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |